FDA clears absorbable soft-tissue marker from Augmenix

01/29/2013 | AuntMinnie.com (free registration)

The FDA has given Augmenix 510(k) clearance to market TraceIT, an injectable synthetic hydrogel used to mark soft tissue radiographically before surgery. The technology, which can be viewed through MRI and other ultrasound modalities, is designed to help streamline image fusion and enhance soft-tissue alignment.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC